News AI helping us make smarter, faster decisions, says Novartis ... Novartis is trialling artificial intelligence (AI) in settings across drug discovery and drug development to help its scientists improve decision making.
Views & Analysis 2016 saw slump in FDA drug approvals, but 2017 could be retu... FDA approvals could rebound in 2017 - but concerns about big pharma R&D productivity won't go away.
News Dupixent is first FDA-approved drug for rare skin disease The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face